TY - CHAP
T1 - Discovery, development, and mechanisms of action of the human CD38 antibody daratumumab
AU - Janmaat, Maarten L.
AU - van de Donk, Niels W. C. J.
AU - van Bueren, Jeroen Lammerts
AU - Ahmadi, Tahamtan
AU - Sasser, A. Kate
AU - Jansson, Richard K.
AU - Lokhorst, Henk M.
AU - Parren, Paul W. H. I.
PY - 2018/4/16
Y1 - 2018/4/16
N2 - This chapter focuses on the discovery and development of the CD38-targeting antibody daratumumab, which formed the basis of the current success in the clinic. In humans, specific single nucleotide polymorphisms of the human CD38 gene have been associated with an increased risk to develop autism spectrum disorders. The discovery of daratumumab started with the selection of CD38 as target for antibody therapeutics. The chapter then provides the context of other emerging antibody therapies in myeloma. The chapter describes the development of daratumumab-based combination therapy for the treatment of multiple myeloma (MM). The daratumumab engages multiple mechanisms of action that contribute to its antitumor efficacy. Daratumumab showed single-agent antitumor activity in heavily pretreated MM patients and is approved as monotherapy in various countries including the United States and in Europe for the treatment of relapsed/refractory MM.
AB - This chapter focuses on the discovery and development of the CD38-targeting antibody daratumumab, which formed the basis of the current success in the clinic. In humans, specific single nucleotide polymorphisms of the human CD38 gene have been associated with an increased risk to develop autism spectrum disorders. The discovery of daratumumab started with the selection of CD38 as target for antibody therapeutics. The chapter then provides the context of other emerging antibody therapies in myeloma. The chapter describes the development of daratumumab-based combination therapy for the treatment of multiple myeloma (MM). The daratumumab engages multiple mechanisms of action that contribute to its antitumor efficacy. Daratumumab showed single-agent antitumor activity in heavily pretreated MM patients and is approved as monotherapy in various countries including the United States and in Europe for the treatment of relapsed/refractory MM.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85100227677&origin=inward
U2 - https://doi.org/10.1002/9783527808694.ch7
DO - https://doi.org/10.1002/9783527808694.ch7
M3 - Chapter
SN - 9783527343034
VL - 3
T3 - Successful Drug Discovery
SP - 153
EP - 195
BT - Successful Drug Discovery
PB - Wiley
ER -